2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
2016
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology 2016, 30: 1099-103, 1106-8. PMID: 27987203, PMCID: PMC7440297.Peer-Reviewed Original ResearchConceptsRecurrent Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAutologous stem cell transplantationMedical literatureAppropriateness of imagingInnovative targeted therapiesCombined-modality therapyLow-dose therapyACR Appropriateness CriteriaEarly-stage diseaseStem cell transplantationMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literaturePeer-reviewed journalsRecurrent diseaseSalvage optionCell transplantationTargeted therapyClinical conditionsACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensity
1999
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1996
Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy
Nath R, Roberts K. Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 977-979. PMID: 8960533, DOI: 10.1016/s0360-3016(96)00441-5.Peer-Reviewed Original Research
1992
Combined chemotherapy and radiotherapy for Hodgkin's disease.
Prosnitz L, Roberts K. Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 1992, 6: 113-28; discussion 131-2, 137. PMID: 1533138.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombined chemotherapyIntermediate-stage Hodgkin's diseaseSecond malignant neoplasmsStage Hodgkin's diseaseAdvanced Hodgkin's diseaseFrequency of relapsesSignificant adverse effectsConsolidation radiationComplete remissionConsolidation radiotherapyModality therapyCombination chemotherapyComplete responseField radiotherapyRelapse frequencyMalignant neoplasmsStandard treatmentLow doseChemotherapyRadiotherapyDiseaseRelapseAdverse effectsPatients